Levemir Penfill

Levemir Penfill


Brand: Novo Nordisk
Availability: In Stock

Out of stock

Product Description

Levemir Penfill is an antidiabetic drug. Levemir Penfill is a soluble analog of human basal insulin, which has a long-lasting effect. For levemir Penfill’s solution, there is no significant peak in activity.
Predictability of the solution effect Levemir Penfill in clinical studies was higher than that of insulin glargine and neutral protamine-insulin Hagedorn.
The long-term effect of the drug is due to a significant relationship between the molecules of the active substance, as well as the addition of albumins through the side chains of fatty acids at the site of administration of the drug. In comparison with neutral protamine-insulin Hagedorn, the active substance of the solution, Leveemir Penfill, is distributed much more slowly in the target tissues. Thanks to these mechanisms, the duration and severity of the action of insulin detemir is more predictable.
The hypoglycemic effect of the Levemir Penfill solution is associated with an increase in glucose uptake by muscle and adipose tissue after binding of specific receptors to insulin, as well as a decrease in the release of glucose from the liver.
The hypoglycemic effect of the Levemir Penfill solution lasts up to 24 hours and can vary depending on the dose. Due to prolonged action, patients can use Levemir Penfill’s solution 1 or 2 times a day. When using the drug twice a day, correction of glycemia is recorded after 2-3 injections. It is noted that more than 50% of the maximal effect of insulin detemir reaches 3-4 hours after the administration of 0.2-0.4 units / kg of the patient’s weight (the duration of the pronounced hypoglycemic effect after the administration of this dose is 14 hours).

Dosing and Administration

Levemir Penfill is intended for subcutaneous administration. The dose and the frequency of administration of the drug Levemir Penfill is determined individually in each specific case. Treatment with Levemir Penfill in combination with oral hypoglycemic drugs, it is recommended to start once a day at a dose of 10 ED or 0.1-0.2 U / kg. The dose of Levemir Penfill should be selected individually based on plasma glucose. If Levemir Penfill is used as part of the basal bolus regimen, it should be administered 1 or 2 times a day based on the patient’s need. Patients who require the use of the drug twice a day for optimal control of the level of glycemia can enter an evening dose either during dinner, or at bedtime, or 12 hours after the morning dose. Levemir Penfill is injected subcutaneously into the thigh, anterior abdominal wall or shoulder area. The injection sites should be changed even when administered to the same area.

Drug Interactions

Hypoglycemic action of insulin enhances oral hypoglycemic drugs, MAO inhibitors, ACE inhibitors, carbonic anhydrase inhibitors, nonselective beta adrenoblockers, bromocriptine, sulfonamides, anabolic steroids, tetracyclines, clofibrate, ketoconazole, mebendazole, pyridoxine, theophylline, cyclophosphamide, fenfluramine, lithium preparations, Containing ethanol.

The hypoglycemic effect of insulin is weakened by oral contraceptives, GCS, iodine-containing thyroid hormones, somatotropin, thiazide diuretics, heparin, tricyclic antidepressants, sympathomimetics, danazol, clonidine, slow calcium channel blockers, diazoxide, morphine, phenytoin, nicotine.

Under the influence of reserpine and salicylates, both weakening and enhancement of the action of the drug are possible.